Previous Close | 48.81 |
Open | 48.81 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 60.00 |
Expire Date | 2024-06-21 |
Day's Range | 48.81 - 48.81 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
Moderna is on the rise after the Food and Drug Administration delayed a decision on its RSV vaccine. But is MRNA stock, once again, a buy?
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.